<DOC>
	<DOCNO>NCT00694382</DOCNO>
	<brief_summary>The primary objective compare efficacy daily subcutaneous injection Semuloparin sodium ( AVE5026 ) placebo prevention venous thromboembolism [ VTE ] cancer patient high risk VTE undergoing chemotherapy . The secondary objective evaluate safety Semuloparin sodium ( AVE5026 ) , document Semuloparin sodium ( AVE5026 ) exposures , try identify metagene predictor VTE ass survival status one year population .</brief_summary>
	<brief_title>Evaluation AVE5026 Prevention Venous Thromboembolism Cancer Patients Undergoing Chemotherapy</brief_title>
	<detailed_description>Randomization take place prior first study drug injection ( randomization ratio 1:1 ) . The study period per participant variable depend duration chemotherapy . It include : - screening period 3 week , - double-blind treatment period , - follow-up period 1 month . Study end date late 7 month follow randomization last participant ( 6 month treatment 1 month follow-up ) .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Cancer patient metastatic locally advanced solid tumor lung , pancreas , stomach , colon/rectum , bladder ovary initiating ( new ) course chemotherapy minimum intent 3 month therapy Required systematic venous thromboprophylaxis curative treatment anticoagulant thrombolytic ; High risk bleeding ; Severe renal impairment ( estimate creatinine clearance &lt; 30 mL/min ) ; ECOG ( Eastern Cooperative Oncology Group ) performance status 3 &amp; 4 ; Major surgery within 4 week randomization ; Known hypersensitivity unfractionated heparin [ UFH ] low molecular weight heparin [ LMWH ] . The information intend contain consideration relevant patient 's potential participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>chemotherapy</keyword>
</DOC>